Novo is teaming up with AI company Anthropic in a new collaboration aimed at accelerating drug discovery, advancing AI-driven software development and helping bring new medicines to patients faster.

 

Under the partnership, the companies will work together on key drug discovery challenges identified by Novo’s scientists and computational teams. They will develop targeted AI solutions for scientific workflows, with a focus on biological reasoning and accelerating the discovery and development of new medicines.

 

“This partnership is another testament to our ambition to become the world’s most AI-driven healthcare company, building on Novo's current AI initiatives with other technology partners. Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,“ said Mike Doustdar, president and CEO of Novo. 

 

“AI can help us increase productivity in R&D and compress the path from research to marketed product. But beyond this, AI tools can also offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics.”

 

As an initial step, Novo will test Claude Science across selected R&D workflows, targeting scientific problems where the combined capabilities of the two companies are expected to deliver the greatest impact.

 

"AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade," said Dario Amodei, co-founder and CEO of Anthropic. 

 

“By giving leading researchers access to safe, capable, and trusted frontier models, we can shorten research timelines, improve outcomes, and discover medicines and treatments that significantly improve human life. That is exactly what our collaboration with Novo is built to achieve.”

 

The partnership will also see Novo use Anthropic’s frontier AI models to strengthen software development, a key component of the company’s efforts to scale AI across its operations.

 

Both companies said the collaboration will operate under robust data governance and human oversight, with safeguards intended to ensure AI is deployed responsibly and in line with Novo's ethical and compliance standards.